Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) EBITDA Margin (2021 - 2023)

Senti Biosciences has reported EBITDA Margin over the past 3 years, most recently at 4415.09% for Q3 2023.

  • Quarterly results put EBITDA Margin at 4415.09% for Q3 2023, down 331746.0% from a year ago — trailing twelve months through Jun 2024 was 16850.0% (down 1481311.0% YoY), and the annual figure for FY2025 was 279263.64%, changed.
  • EBITDA Margin for Q3 2023 was 4415.09% at Senti Biosciences, down from 2721.98% in the prior quarter.
  • Over the last five years, EBITDA Margin for SNTI hit a ceiling of 1042.6% in Q2 2022 and a floor of 30862.71% in Q4 2022.
  • Median EBITDA Margin over the past 3 years was 1499.5% (2021), compared with a mean of 4881.62%.
  • Peak annual rise in EBITDA Margin hit 50072bps in 2022, while the deepest fall reached -2748686bps in 2022.
  • Senti Biosciences' EBITDA Margin stood at 3375.85% in 2021, then plummeted by -814bps to 30862.71% in 2022, then soared by 86bps to 4415.09% in 2023.
  • The last three reported values for EBITDA Margin were 4415.09% (Q3 2023), 2721.98% (Q2 2023), and 1455.68% (Q1 2023) per Business Quant data.